Inflammatory Bowel Disease Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | AbbVie, Janssen Pharma, Abivax, Morphic Therapeutic, Eli Lilly and Company, Gilead

The Key Inflammatory Bowel Disease Companies: AbbVie, Janssen Pharmaceuticals, Abivax, Morphic Therapeutic, CJ Bioscience/4D Pharma, RedHill Biopharma, Tryp Therapeutics, Eli Lilly and Company, Gilead, Galapagos, Applied Molecular Transport, Protagonist Therapeutics, Janssen, AstraZeneca, Vifor Pharma, Astellas Pharma, Shield Therapeutics, Takeda, Ocera Therapeutics, Sanofi, Morphic Therapeutic, Inc., Bausch Health Americas, Inc., Qu Biologics Inc., Vifor Pharma, and others
DelveInsight's "Inflammatory Bowel Disease Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Inflammatory Bowel Disease, historical and forecasted epidemiology as well as the Inflammatory Bowel Disease market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Inflammatory Bowel Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Inflammatory Bowel Disease Market Forecast [https://www.delveinsight.com/sample-request/inflammatory-bowel-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Inflammatory Bowel Disease Market Report:

*
The Inflammatory Bowel Disease market size is anticipated to grow with a significant CAGR during the study period (2020-2034).

*
In September 2025, With the latest FDA approval, Johnson & Johnson strengthened Tremfya's position in the inflammatory bowel disease (IBD) space, marking a milestone for the IL-23 inhibitor class. The FDA has approved a subcutaneous (SC) induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis (UC). This new approval builds on Tremfya's earlier intravenous (IV) approval in UC granted last September, making it the first IL-23 inhibitor to offer both SC and IV dosing options from induction to maintenance therapy for Inflammatory Bowel Disease (IBD) patients, according to Johnson & Johnson's press release.

*
In May 2025, ALPCO introduced its Calprotectin Immunoturbidimetric Assay in Europe to aid in diagnosing inflammatory bowel disease (IBD), such as Crohn's disease and ulcerative colitis. The assay, already FDA-cleared and IVDD-certified, is designed to help differentiate IBD from irritable bowel syndrome (IBS) when combined with other clinical information.

*
In January 2025, Eli Lilly and Company reported that the U.S. Food and Drug Administration (FDA) has granted approval to Omvoh Registered (mirikizumab-mrkz) for adults with moderately to severely active Crohn's disease. With this approval, Omvoh is now authorized in the U.S. for two inflammatory bowel diseases (IBD), following its October 2023 approval as the first-in-class therapy for moderately to severely active ulcerative colitis (UC) in adults.

*
In September 2023, Cosmo Pharmaceuticals and Adalvo entered into a license and supply agreement for Rifamycin SV with MMX technology across Europe, Asia-Pacific (APAC), Middle East/North Africa (MENA), and Latin America (LATAM) regions.

*
In May 2023, NGM Biopharmaceuticals announced that findings from a Phase II investigator-sponsored trial of aldafermin for treating patients with idiopathic bile acid malabsorption (BAM) alongside irritable bowel syndrome with diarrhea (IBS-D) were presented at Digestive Disease Week 2023.

*
In 2023, the United States had the largest number of cases among the 7MM, with approximately 14 million prevalent cases. These numbers are anticipated to rise in the forecast period.

*
In the United States in 2023, irritable bowel syndrome was more prevalent among females than males in terms of total gender-specific cases.

*
In 2023, Germany had the highest prevalence of irritable bowel syndrome among the EU4 and the UK, whereas Spain reported the lowest number of cases.

*
According to Breen-Lyles et al. (2023), the average symptom severity score of irritable bowel syndrome in patients meeting Rome IV criteria was notably higher compared to those meeting Rome III criteria.

*
According to the American College of Gastroenterology (2023), irritable bowel syndrome is prevalent, impacting approximately 5% of the population, which equates to about 1 in 20 individuals in the US.

*
Key Inflammatory Bowel Disease Companies: AbbVie, Janssen Pharmaceuticals, Abivax, Morphic Therapeutic, CJ Bioscience/4D Pharma, RedHill Biopharma, Tryp Therapeutics, Eli Lilly and Company, Gilead, Galapagos, Applied Molecular Transport, Protagonist Therapeutics, Janssen, AstraZeneca, Pharmacosmos A/S, 4SC AG, Pharmacosmos A/S, Vifor Pharma, Astellas Pharma, Shield Therapeutics, Takeda, Ocera Therapeutics, Sanofi, Morphic Therapeutic, Inc., Bausch Health Americas, Inc., Qu Biologics Inc., Vifor Pharma, and others

*
Key Inflammatory Bowel Disease Therapies: RINVOQ (upadacitinib), STELARA (ustekinumab), Obefazimod, MORF-057, Blautix, BEKINDA (RHB-102), TRP-8802, Mirikizumab, Filgotinib, AMT-101, PN-943, Tremfya, Brazikumab, Iron Isomaltoside 1000, SC12267 (4SC-101), Monofer, Ferinject, fidaxomicin, Ferric Maltol, Lubiprostone, AST-120, Ustekinumab, Nolpitantium besylate, MORF-057, Balsalazide Disodium, QBECO, Ferric carboxymaltose, and others

*
The Inflammatory Bowel Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Inflammatory Bowel Disease pipeline products will significantly revolutionize the Inflammatory Bowel Disease market dynamics.

Inflammatory Bowel Disease Overview

Irritable Bowel Syndrome (IBS) is a common disorder that affects the large intestine (colon). It is characterized by a group of symptoms that occur together, including abdominal pain or discomfort, bloating, and changes in bowel habits such as diarrhea, constipation, or both. IBS is a chronic condition that can vary in severity and typically requires long-term management.

Get a Free sample for the Inflammatory Bowel Disease Market Report:

https://www.delveinsight.com/report-store/inflammatory-bowel-disease-market [https://www.delveinsight.com/report-store/inflammatory-bowel-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Inflammatory Bowel Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Inflammatory Bowel Disease Epidemiology Segmentation:

The Inflammatory Bowel Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalent Cases of Irritable Bowel Syndrome in the 7MM

*
Total Diagnosed Prevalent Cases of Irritable Bowel Syndrome in the 7MM

*
Gender-specific Prevalent Cases of Irritable Bowel Syndrome in the 7MM

*
Age-specific Prevalent Cases of Irritable Bowel Syndrome in the 7MM

*
Severity-specific Diagnosed Prevalent Cases of Irritable Bowel Syndrome in the 7MM

*
Subtype-specific Diagnosed Prevalent Cases of Irritable Bowel Syndrome in the 7MM

*
Total Treated Cases of Irritable Bowel Syndrome in the 7MM

Download the report to understand which factors are driving Inflammatory Bowel Disease epidemiology trends @ Inflammatory Bowel Disease Epidemiology Forecast [https://www.delveinsight.com/sample-request/inflammatory-bowel-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Inflammatory Bowel Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Inflammatory Bowel Disease market or expected to get launched during the study period. The analysis covers Inflammatory Bowel Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Inflammatory Bowel Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Inflammatory Bowel Disease Therapies and Key Companies

*
RINVOQ (upadacitinib): AbbVie

*
STELARA (ustekinumab): Janssen Pharmaceuticals

*
Obefazimod: Abivax

*
MORF-057: Morphic Therapeutic

*
Blautix: CJ Bioscience/4D Pharma

*
BEKINDA (RHB-102): RedHill Biopharma

*
TRP-8802: Tryp Therapeutics

*
Mirikizumab: Eli Lilly and Company

*
Filgotinib: Gilead/ Galapagos

*
AMT-101: Applied Molecular Transport

*
PN-943: Protagonist Therapeutics

*
Tremfya: Janssen

*
Brazikumab: AstraZeneca

Inflammatory Bowel Disease Market Strengths

*
The high prevalence of irritable bowel syndrome is the primary strength of its global market, leading to more focus by pharmaceutical firms.

*
Approved drugs to treat irritable bowel syndrome in adults are being studied in pediatric groups as well.

Inflammatory Bowel Disease Market Opportunities

*
Treating the pathophysiological causative agent responsible for the symptoms is an emerging approach.

*
It is hoped that as the application for the irritable bowel syndrome diagnostic grows, it will play a role in earlier diagnosis of irritable bowel syndrome as well as obviating the need for another unnecessary testing.

Discover more about therapies set to grab major Inflammatory Bowel Disease market share @ Inflammatory Bowel Disease Treatment Market [https://www.delveinsight.com/sample-request/inflammatory-bowel-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Scope of the Inflammatory Bowel Disease Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Inflammatory Bowel Disease Companies: AbbVie, Janssen Pharmaceuticals, Abivax, Morphic Therapeutic, CJ Bioscience/4D Pharma, RedHill Biopharma, Tryp Therapeutics, Eli Lilly and Company, Gilead, Galapagos, Applied Molecular Transport, Protagonist Therapeutics, Janssen, AstraZeneca, Pharmacosmos A/S, 4SC AG, Pharmacosmos A/S, Vifor Pharma, Astellas Pharma, Shield Therapeutics, Takeda, Ocera Therapeutics, Sanofi, Morphic Therapeutic, Inc., Bausch Health Americas, Inc., Qu Biologics Inc., Vifor Pharma, and others

*
Key Inflammatory Bowel Disease Therapies: RINVOQ (upadacitinib), STELARA (ustekinumab), Obefazimod, MORF-057, Blautix, BEKINDA (RHB-102), TRP-8802, Mirikizumab, Filgotinib, AMT-101, PN-943, Tremfya, Brazikumab, Iron Isomaltoside 1000, SC12267 (4SC-101), Monofer, Ferinject, fidaxomicin, Ferric Maltol, Lubiprostone, AST-120, Ustekinumab, Nolpitantium besylate, MORF-057, Balsalazide Disodium, QBECO, Ferric carboxymaltose, and others

*
Inflammatory Bowel Disease Therapeutic Assessment: Inflammatory Bowel Disease current marketed and Inflammatory Bowel Disease emerging therapies

*
Inflammatory Bowel Disease Market Dynamics: Inflammatory Bowel Disease market drivers and Inflammatory Bowel Disease market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Inflammatory Bowel Disease Unmet Needs, KOL's views, Analyst's views, Inflammatory Bowel Disease Market Access and Reimbursement

To know more about Inflammatory Bowel Disease companies working in the treatment market, visit @ Inflammatory Bowel Disease Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/inflammatory-bowel-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Inflammatory Bowel Disease Market Report Introduction

2. Executive Summary for Inflammatory Bowel Disease

3. SWOT analysis of Inflammatory Bowel Disease

4. Inflammatory Bowel Disease Patient Share (%) Overview at a Glance

5. Inflammatory Bowel Disease Market Overview at a Glance

6. Inflammatory Bowel Disease Disease Background and Overview

7. Inflammatory Bowel Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Inflammatory Bowel Disease

9. Inflammatory Bowel Disease Current Treatment and Medical Practices

10. Inflammatory Bowel Disease Unmet Needs

11. Inflammatory Bowel Disease Emerging Therapies

12. Inflammatory Bowel Disease Market Outlook

13. Country-Wise Inflammatory Bowel Disease Market Analysis (2020-2034)

14. Inflammatory Bowel Disease Market Access and Reimbursement of Therapies

15. Inflammatory Bowel Disease Market Drivers

16. Inflammatory Bowel Disease Market Barriers

17. Inflammatory Bowel Disease Appendix

18. Inflammatory Bowel Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=inflammatory-bowel-disease-market-positioned-for-accelerated-development-through-2034-delveinsight-finds-abbvie-janssen-pharma-abivax-morphic-therapeutic-eli-lilly-and-company-gilead]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.